Literature DB >> 11372645

A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi.

T Hamouda1, A Myc, B Donovan, A Y Shih, J D Reuter, J R Baker.   

Abstract

A novel non-ionic surfactant nanoemulsion designated 8N8 has been tested for its biocidal activity. One percent 8N8 produced effective bactericidal activity against Bacillus cereus, Bacillus subtilis, Haemophilus influenzae, Neisseria gonorrhoeae, Streptococcus pneumoniae, and Vibrio cholerae in 15 minutes. In contrast, most enteric gram-negative bacteria were resistant to 8N8. One percent 8N8 was also virucidal within 15 minutes for all tested enveloped viruses, including Herpes simplex type 1, influenza A and vaccinia viruses. One percent 8N8 also demonstrated fungistatic activity on Candida albicans. The rapid and non-specific inactivation of vegetative bacteria and enveloped viruses, in addition to its fungistatic activity and low toxicity in experimental animals, makes 8N8 a potential candidate for use as a topical biocidal agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372645     DOI: 10.1078/0944-5013-00069

Source DB:  PubMed          Journal:  Microbiol Res        ISSN: 0944-5013            Impact factor:   5.415


  43 in total

1.  Emerging role of nanoemulsions in oral health management.

Authors:  Jasjeet Kaur Narang; Ramandeep Singh Narang
Journal:  Int J Pharm Investig       Date:  2017 Jan-Mar

2.  Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Authors:  P E Makidon; J Knowlton; J V Groom; L P Blanco; J J LiPuma; A U Bielinska; J R Baker
Journal:  Med Microbiol Immunol       Date:  2009-12-06       Impact factor: 3.402

3.  Nanomedicine in the Management of Microbial Infection - Overview and Perspectives.

Authors:  Xi Zhu; Aleksandar F Radovic-Moreno; Jun Wu; Robert Langer; Jinjun Shi
Journal:  Nano Today       Date:  2014-08-01       Impact factor: 20.722

4.  In vitro antibacterial activity of NB-003 against Propionibacterium acnes.

Authors:  J Pannu; A McCarthy; A Martin; T Hamouda; S Ciotti; L Ma; J Sutcliffe; J R Baker
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

5.  Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.

Authors:  Andrzej Myc; Jolanta F Kukowska-Latallo; Douglas M Smith; Crystal Passmore; Tiffany Pham; Pamela Wong; Anna U Bielinska; James R Baker
Journal:  Vaccine       Date:  2012-12-25       Impact factor: 3.641

6.  Antimicrobial activity of nanoemulsion on cariogenic planktonic and biofilm organisms.

Authors:  Karthikeyan Ramalingam; Bennett T Amaechi; Rawls H Ralph; Valerie A Lee
Journal:  Arch Oral Biol       Date:  2011-07-31       Impact factor: 2.633

7.  Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury.

Authors:  Mark R Hemmila; Aladdein Mattar; Michael A Taddonio; Saman Arbabi; Tarek Hamouda; Peter A Ward; Stewart C Wang; James R Baker
Journal:  Surgery       Date:  2010-03-02       Impact factor: 3.982

8.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Biosynthesis and characterization of silver nanoparticles produced by Pleurotus ostreatus and their anticandidal and anticancer activities.

Authors:  Ramy S Yehia; Hashem Al-Sheikh
Journal:  World J Microbiol Biotechnol       Date:  2014-07-23       Impact factor: 3.312

10.  Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Authors:  Subash C Das; Masato Hatta; Peter R Wilker; Andrzej Myc; Tarek Hamouda; Gabrielle Neumann; James R Baker; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2012-09-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.